Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Jingbo Hu, Aiping Deng & Yufen Zhao. (2018) Ertugliflozin as a monotherapy for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 19:16, pages 1841-1847.
Read now
Read now
Hiroyuki Ito, Masahiro Shinozaki, Shinya Nishio & Mariko Abe. (2016) SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. Expert Opinion on Pharmacotherapy 17:15, pages 2073-2084.
Read now
Read now
Xueying Tan & Jingbo Hu. (2016) Combination therapy for type 2 diabetes: dapagliflozin plus metformin. Expert Opinion on Pharmacotherapy 17:1, pages 117-126.
Read now
Read now
Kalliopi Pafili & Nikolaos Papanas. (2015) Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?. Expert Opinion on Pharmacotherapy 16:4, pages 453-456.
Read now
Read now
Manfredi Rizzo, Noor Al-Busaidi & Ali A Rizvi. (2015) Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Expert Opinion on Pharmacotherapy 16:3, pages 281-284.
Read now
Read now
Kalliopi Pafili & Nikolaos Papanas. (2014) Tofogliflozin: the road goes ever on. Expert Opinion on Pharmacotherapy 15:9, pages 1197-1201.
Read now
Read now
Angela J Paisley, Rahul Yadav, Naveed Younis, Prasanna Rao-Balakrishna & Handrean Soran. (2013)
Dapagliflozin: a review on efficacy, clinical effectiveness and safety. Expert Opinion on Investigational Drugs 22:1, pages 131-140.
Read now
Read now
Articles from other publishers (26)
Xiaoying Zhao, Rui Ning, Andrew Hui, David W. Boulton & Weifeng Tang. (2023) Pharmacokinetic Variables of Dapagliflozin/Metformin Extended-Release Fixed-Dose Combination in Healthy Chinese Volunteers and Regional Comparison. Clinical Therapeutics.
Crossref
Crossref
Michał Szklarz, Katarzyna Gontarz-Nowak, Wojciech Matuszewski & Elżbieta Bandurska-Stankiewicz. (2022) Can Iron Play a Crucial Role in Maintaining Cardiovascular Health in the 21st Century?. International Journal of Environmental Research and Public Health 19:19, pages 11990.
Crossref
Crossref
Yousef Faridvand, Hamid Kazemzadeh, Vahid Vahedian, Pourya Mirzajanzadeh, Hamid Reza Nejabati, Nasser Safaie, Nazila Fathi Maroufi, Masoud Pezeshkian, Mohammad Nouri & Ahmadreza Jodati. (2022)
Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through
AMPK
/
SIRT1
activation
. Clinical and Experimental Pharmacology and Physiology 49:6, pages 643-651.
Crossref
Crossref
Niki Katsiki, George D. Dimitriadis & Dimitri P. Mikhailidis. (2021) Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease. Current Pharmaceutical Design 27:16, pages 1941-1951.
Crossref
Crossref
Niki Katsiki, Kalliopi Kotsa, Anca P. Stoian & Dimitri P. Mikhailidis. (2020) Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes. Current Pharmaceutical Design 26:43, pages 5637-5649.
Crossref
Crossref
Jing Huang, Shuyuan Xiong, Shenglan Ding, Qingfeng Cheng & Zhiping Liu. (2020) Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research 2020, pages 1-13.
Crossref
Crossref
Niki Katsiki & Ele Ferrannini. (2020) Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?. Journal of Diabetes and its Complications 34:12, pages 107723.
Crossref
Crossref
Niki Katsiki & Dimitri P. Mikhailidis. (2019) Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)?. Journal of Diabetes and its Complications 33:11, pages 107408.
Crossref
Crossref
Dong-Gyun Han, Hwayoung Yun & In-Soo Yoon. (2019) A novel high-performance liquid chromatographic method combined with fluorescence detection for determination of ertugliflozin in rat plasma: Assessment of pharmacokinetic drug interaction potential of ertugliflozin with mefenamic acid and ketoconazole. Journal of Chromatography B 1122-1123, pages 49-57.
Crossref
Crossref
Niki Katsiki, George Dimitriadis, George Hahalis, Nikolaos Papanas, Nikolaos Tentolouris, Filippos Triposkiadis, Vasilios Tsimihodimos, Costas Tsioufis, Dimitri P. Mikhailidis & Christos Mantzoros. (2019) Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metabolism 96, pages 92-100.
Crossref
Crossref
Subhankar Chatterjee, Dhrubajyoti Bandyopadhyay, Raktim K. Ghosh, Uddalak Majumdar, Ashish Aneja, Carl J. Lavie & Prakash Deedwania. (2019) SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality?. Current Problems in Cardiology 44:7, pages 207-222.
Crossref
Crossref
Niki Katsiki & Filippos Triposkiadis. (2019) Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?. Current Vascular Pharmacology 17:4, pages 421-424.
Crossref
Crossref
ManashPratim Baruah, BM Makkar, VikrantB Ghatnatti & Kaushik Mandal. (2019) Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control. Indian Journal of Endocrinology and Metabolism 23:1, pages 140.
Crossref
Crossref
Tracey Gaspari, Iressa Spizzo, HongBin Liu, Yunshan Hu, Richard W Simpson, Robert E Widdop & Anthony E Dear. (2017) Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis. Diabetes and Vascular Disease Research 15:1, pages 64-73.
Crossref
Crossref
Niki Katsiki, Dimitri P. Mikhailidis & Christos S. Mantzoros. (2016) Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 65:8, pages 1109-1123.
Crossref
Crossref
Andrew Collier, Angus Stirling, Lyall Cameron, Mario Hair & David Crosbie. (2016) Gout and diabetes: a common combination. Postgraduate Medical Journal 92:1089, pages 372-378.
Crossref
Crossref
Sho-ichi YamagishiTakanori Matsui. (2016) Protective Role of Sodium–Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes. Rejuvenation Research 19:2, pages 107-114.
Crossref
Crossref
Tjerk W.A. de Bruin, Stots Reele, Jennifer E. Hamer-Maansson, Shamik Parikh & Weifeng Tang. (2016) Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. Clinical Pharmacology in Drug Development 5:2, pages 118-130.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
419
458
.
Ming Chang, Xiaoni Liu, Dapeng Cui, Dan Liang, Frank LaCreta, Steven C. Griffen, Susan Lubin, Donette Quamina‐Edghill & David W. Boulton. (2015) Bioequivalence, Food Effect, and Steady‐State Assessment of Dapagliflozin/Metformin Extended‐release Fixed‐dose Combination Tablets Relative to Single‐component Dapagliflozin and Metformin Extended‐release Tablets in Healthy Subjects. Clinical Therapeutics 37:7, pages 1517-1528.
Crossref
Crossref
Armin Bauer & Mark Brönstrup. (2014) Industrial natural product chemistry for drug discovery and development. Nat. Prod. Rep. 31:1, pages 35-60.
Crossref
Crossref
S. Cangoz, Y.-Y. Chang, S. J. Chempakaseril, R. C. Guduru, L. M. Huynh, J. S. John, S. T. John, M. E. Joseph, R. Judge, R. Kimmey, K. Kudratov, P. J. Lee, I. C. Madhani, P. J. Shim, S. Singh, S. Singh, C. Ruchalski & R. B. Raffa. (2013) The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. Journal of Clinical Pharmacy and Therapeutics 38:5, pages 350-359.
Crossref
Crossref
T. Heise, E. Seewaldt‐Becker, S. Macha, S. Hantel, S. Pinnetti, L. Seman & H. J. Woerle. (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 15:7, pages 613-621.
Crossref
Crossref
S. Macha, P. Rose, M. Mattheus, S. Pinnetti & H. J. Woerle. (2012) Lack of drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes, Obesity and Metabolism 15:4, pages 316-323.
Crossref
Crossref
Ana B. Bueno, Ana M. Castaño & Ángel Rodríguez. 2013. Drug Discovery. Drug Discovery
205
243
.
Arne Ring, Tobias Brand, Sreeraj Macha, Kerstin Breithaupt-Groegler, Gudrun Simons, Beate Walter, Hans J Woerle & Uli C Broedl. (2013) The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovascular Diabetology 12:1, pages 70.
Crossref
Crossref